Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
Date:11/9/2010

ly attributable to increased legal and marketing research expenses. General and administrative expenses in the first nine months of 2010 included $1.7 million in non-cash, share-based compensation expense, compared to $2.2 million in the first nine months of 2009. Total interest and other expense increased to $22.4 million in the first nine months of 2010, compared to $13.7 million in the first nine months of 2009. This increase is primarily attributable to increases in the loss on extinguishment of debt, a non-cash item, and interest expense, both related to Arena's loan from certain Deerfield entities.

At September 30, 2010, cash, cash equivalents and short-term investments totaled $176.5 million and approximately 121.4 million shares of common stock were outstanding.

Arena's Recent and Third Quarter Developments Lorcaserin

  • Announced top-line results from the lorcaserin BLOOM-DM trial that demonstrate statistically significant weight loss and improved HbA1c in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three primary efficacy endpoints.
  • The US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. In the CRL, the FDA stated that it has completed its review of the NDA and determined that it cannot approve the application in its present form. The FDA also outlined non-clinical and clinical reasons for its decision and provided recommendations relating to addressing such issues. Prior to issuance of the CRL, the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted nine to five that the available data do not demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long term in a population of overweight and obese individuals to allow marketing approval.
  • Results from a lorcaserin mechanism of action study conducted at the Pennington Biomedical Research Cent
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
    2. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
    3. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
    4. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
    5. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
    6. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
    7. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
    8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
    9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
    10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
    (Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
    (Date:1/23/2015)... Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of ... compound, LB‑100, is being conducted, has been expanded from 1 ... M.D., the founder and President of Lixte, said that, "the ... site. Accrual of patients, however, was slower than projected. The ...
    Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
    ... announces the release of its newest report, Capitalizing ... a sluggish economy and cuts being made to laboratory budgets, ... increase substantially over the next several years to $688.9 M ... of 2011. Suppliers of stem cell related products are ...
    ... (Nasdaq: TSPT ), a specialty pharmaceutical company ... that address important therapeutic needs in the field of ... first quarter 2009 on Wednesday, May 13, 2009, after ... begin at 5:00 p.m. ET (2:00 p.m. PT) on ...
    Cached Medicine Technology:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available 2BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available 3Transcept Pharmaceuticals to Report First Quarter 2009 Results 2Transcept Pharmaceuticals to Report First Quarter 2009 Results 3
    (Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
    (Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
    (Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
    (Date:1/22/2015)... January 22, 2015 Step into a ... the Science Museum of Virginia. Wicked Plants, the Museum’s ... Plants unearths 75 poisonous, carnivorous and diabolical plants inside ... room to uncover the biochemical, physical and neurological processes ...
    Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
    ... -- Restricting carbohydrates, regardless of weight loss, appears to slow ... being published this week by researchers in the Duke Prostate ... a diet light in carbohydrates could slow tumor growth, but ... we know that weight loss can restrict the amount of ...
    ... care costs at home, nearly 1 million Californians cross ... Mexico, according a new paper by UCLA researchers and ... . , An estimated 952,000 California ... annually, and of these, 488,000 were Mexican immigrants, according ...
    ... One in Four Reports Meeting OfflineCINCINNATI, May 26 ... how their teenage girls present themselves online.The study, published ... girls who would depict themselves online in a provocative ... abuse, are more likely to receive online sexual advances ...
    ... Walk for Lupus Now ... at the Orange County Great Park on Saturday, June 6, 2009. ... Lupus Foundation of America, Inc., an event to raise essential funds ... than 1.5 million Americans. The event promotes physical activity and ...
    ... 30, 2009)When a cancer patient and his or her doctor ... centers on a consideration of the treatment,s medical benefits versus ... the already high costs of cancer care continue to rise, ... into account the economic impact of the treatment on the ...
    ... 2009, Amsterdam, The Netherlands and San Antonio, TX, USA ... of the 2009 Alzheimer Award presented by the Journal ... "Identification of miRNA changes in Alzheimer,s disease brain and CSF ... Dis 14: 27-41, 2008) by J.P. Cogswell et al. ...
    Cached Medicine News:Health News:Carbohydrate restriction may slow prostate tumor growth 2Health News:Nearly 1 million Californians seek medical care in Mexico annually 2Health News:Nearly 1 million Californians seek medical care in Mexico annually 3Health News:Study Demonstrates Internet Risks for Teen Girls 2Health News:Study Demonstrates Internet Risks for Teen Girls 3Health News:Walk for Lupus Now(TM) at the Orange County Great Park 2Health News:Can we afford the cancer care of the future? 2Health News:John P. Cogswell, Ph.D., receives 2009 Alzheimer Award 2
    ... Every Bard® Biopsy Instrument and Needle is ... important goal: a large quality, reliable core ... performance, featuring ultra-sharp tips and polished surfaces ... selection of biopsy systems and needle sizes ...
    ... Used to obtain multiple core biopsies ... Quick-Core® Biopsy Needle design facilitates one-handed control. ... tissue sample. Beveled point stylet permits easy ... to surrounding tissue. Sharp cutting edge of ...
    ... Q-Track i Holter Monitoring System uses technology ... the worlds first true 12-lead digital Holter ... of any beat contained in the 24-hour ... ,The preprocessing work done by the Q-12 ...
    ... incorporates the iQ®200 Automated Urine Microscopy ... AX-4280 Automated Urine Chemistry Analyzer (AX-4280) ... and microscopic analysis. The iQ200 uses ... neural network, to classify and quantitate ...
    Medicine Products: